There is one clinical trial.
The hypothesis to be tested is that acutely ill asthmatics who do not resolve their attacks following standard doses of albuterol and require admission to hospital have single nucleotide polymorphisms of their B2 adrenergic receptors that lower B2 agonist responsivity.
Eleven polymorphisms will be selected for genotyping from within the ADRB2 coding region and up to about 5 kb 5' Codon 1 (rs11958940, rs17778257, rs2895795, rs2053044, rs12654778, rs11959427, rs1042711, rs1042713, rs1042714, rs1800888, and rs1042718).